Oral cavity
Facing added pressure from Eli Lilly, Novo Nordisk submits for FDA approval of oral GLP-1 obesity drug
Nordisk, Obesity, Approved, Oral cavity, Glucagon-Like Peptide 1, Market, Pressure- physical agent, eli lilly, competition, Novo, semaglutide, United States Food and Drug Administration, United States Food and Drug Administration
Lilly’s oral GLP-1 succeeds in first Phase III test, delivering promising weight loss
orforglipron, Glucagon-Like Peptide 1, Weight Loss, Oral cavity, orforglipron, Phase 3 Clinical Trials, Diabetes Mellitus, Non-Insulin-Dependent, Hemoglobin A1c measurement, Safety, Injectables
AstraZeneca’s oral PCSK9 inhibitor halves cholesterol in phase 2 trial
AZD0780, LDL Cholesterol Lipoproteins, AstraZeneca ‘s, Oral cavity, PCSK9 inhibitor, Effectiveness
GLP-1 Injectables Will Soon Be Joined by Orals. Is the Industry Ready to Scale?
Glucagon-Like Peptide 1, Industry, Market, Effectiveness, Oral cavity, production, injectables, Orals, orforglipron, Manufacture, GLP-1s
Opko, Entera share ownership of first oral GLP-1/glucagon agonist set to enter clinic
entera, GLP-1/glucagon, first, Oral cavity, OPKO, Ownership, Entera
Ascletis Advances in Obesity Treatment with Promising Oral GLP-1 Data
Ascletis Pharma, oral GLP-1, obesity treatment, weight loss, ASC30, Chinese biotech, pharmaceutical innovation
Ascletis’ Oral GLP-1 Drug Shows Promising Early Results in Obesity Treatment, Rivaling Roche’s Candidate
Ascletis Pharma, obesity treatment, oral GLP-1 receptor agonist, ASC30, weight loss, clinical trials, Roche, CT-996, pharmaceutical competition
Merck & Co. Enters Oral GLP-1 Market with $2 Billion Hansoh Pharma Deal
Merck & Co., Hansoh Pharma, GLP-1 receptor agonist, oral obesity treatment, pharmaceutical collaboration, biotech partnership
Merck Enters Obesity Market with $2 Billion Deal for Chinese Oral GLP-1 Drug
Merck, Obesity, Oral GLP-1, Hansoh Pharma, HS-10535, Weight Loss, Cardiometabolic Benefits
Iterum Therapeutics Secures FDA Approval for Orlynvah, Breaking Two-Decade Drought in New UTI Treatments
Iterum Therapeutics, FDA Approval, Orlynvah, Uncomplicated Urinary Tract Infections (uUTIs), Sulopenem Etzadroxil and Probenecid, Oral Penem